


2. The method of claim 1 wherein the pathophysiological process is a carcinoma, sarcoma or leukaemia, psoriasis or rheumatoid arthritis.

5 3. A compound of the formula



, wherein:

10 R₁ denotes a hydrogen atom, a C₁₋₃-alkyl or trifluoromethyl group,

R₂ denotes a hydrogen, fluorine, chlorine or bromine atom, a C₁₋₃-alkyl, C₃₋₇-cycloalkyl or C₁₋₃-alkoxy group or, if R₄ and R₅ each denote a hydrogen atom, R₁ and R₂ together denote an n-C₁₋₃-alkylene group optionally substituted by a C₁₋₃-alkyl group,

15

R₃ denotes a hydrogen atom or a C₁₋₅-alkyl group,

R₄ and R₅ each denote a hydrogen atom or together denote another carbon-carbon bond,

20 A denotes a phenyl, naphthyl or tetrahydronaphthyl group substituted by a fluorine, chlorine, bromine or iodine atom, by a C₁₋₆-alkyl, C₃₋₇-cycloalkyl, phenyl, C₁₋₃-alkoxy, cyano, trifluoromethyl or nitro group, whilst the abovementioned monosubstituted phenyl and naphthyl groups may additionally be substituted by a fluorine, chlorine or bromine atom, by a C₁₋₃-alkyl or C₁₋₃-alkoxy group and the abovementioned disubstituted phenyl
25 groups may additionally be substituted by a C₁₋₃-alkyl or C₁₋₃-alkoxy group, with the proviso that

2020FO4552E004

A does not denote a phenyl group which is substituted by a halogen atom, by a methyl, pentyl, C₁₋₃-alkoxy or phenyl group or by two C₁₋₃-alkoxy groups, if

- R₃ denotes a hydrogen atom,
5 R₄ and R₅ each denote a hydrogen atom or
R₄ and R₅ together denote another carbon-carbon bond and
B denotes a carboxyphenyl or methoxycarbonylphenyl group,

and A does not denote a phenyl group substituted by a methyl or phenyl group if

- 10 R₁ and R₂ each denote a hydrogen atom,
R₃ denotes a hydrogen atom,
R₄ and R₅ together denote another carbon-carbon bond and
B denotes a carboxyphenyl or methoxycarbonylphenyl group,
15 a naphthyl group,

a chromane or chromene group wherein a methylene group may be replaced by a carbonyl group,

- 20 a 5- or 6-membered heteroaryl group optionally substituted in the carbon skeleton by a fluorine, chlorine or bromine atom or by a C₁₋₃-alkyl or C₁₋₃-alkoxy group, whilst the 6-membered heteroaryl groups contain one, two or three nitrogen atoms and the 5-membered heteroaryl groups contain an imino group optionally substituted by a C₁₋₃-alkyl group, an oxygen or sulphur atom or an imino group optionally substituted by a C₁₋₃-alkyl group and an oxygen or sulphur atom or one or two nitrogen atoms and additionally a phenyl ring may be fused to the abovementioned monocyclic heteroaryl groups via two adjacent carbon atoms, whilst said phenyl ring may also be substituted in the carbon skeleton by a fluorine, chlorine or bromine atom, by a C₁₋₃-alkyl or C₁₋₃-alkoxy group,
25 30 a phenylvinyl group or

R_1 together with A and the carbon atom between them denote a C_{5-7} -cycloalkylidene group to which a phenyl ring may be fused via two adjacent carbon atoms, whilst said phenyl ring may additionally be substituted by one or two C_{1-3} -alkyl or C_{1-3} -alkoxy groups, whilst
5 the substituents may be identical or different, and

~~B~~ B denotes a 5- or 6-membered heteroaryl group substituted by a carboxy group or by a group which may be converted into a carboxy group *in vivo*,

10 a phenyl or naphthyl group, each of which may be substituted by a carboxy group, by a group which may be converted into a carboxy group *in vivo* or by a group which is negatively charged under physiological conditions, whilst the abovementioned phenyl groups may additionally be substituted

15 by a fluorine, chlorine, bromine or iodine atom,
by a C_{1-3} -alkyl, trifluoromethyl, phenyl, hydroxy, C_{1-3} -alkoxy, C_{1-3} -alkylsulphonyloxy, phenylsulphonyloxy, carboxy, C_{1-3} -alkoxycarbonyl, formyl, C_{1-3} -alkylcarbonyl, C_{1-3} -alkylsulphonyl, phenylsulphonyl, nitro, pyrrolidino, 20 piperidino, morpholino, N-(C_{1-3} -alkyl)-piperazino, aminoulphonyl, C_{1-3} -alkylaminosulphonyl or di-(C_{1-3} -alkyl)-aminosulphonyl group,

25 by a C_{1-3} -alkyl group which is substituted by a hydroxy, C_{1-3} -alkoxy, amino, C_{1-4} -alkylamino, di-(C_{1-4} -alkyl)-amino, C_{3-7} -cycloalkylamino, pyrrolidino, piperidino, morpholino, piperazino or N-(C_{1-3} -alkyl)-piperazino group,

by an n- C_{2-3} -alkoxy, C_{2-3} -alkenyl or C_{2-3} -alkynyl group substituted in the 2 or 3 position by a di-(C_{1-3} -alkyl)-amino group,

30 by an amino group, by an N-(C_{1-3} -alkyl)-amino or N,N-di-(C_{1-3} -alkyl)-amino group wherein the alkyl moiety may in each case be substituted in the 2 or 3 position in

2020 TD * 552601

relation to the nitrogen atom by a C₁₋₃-alkoxy group, by an N-phenylamino, N-(phenyl-C₁₋₃-alkyl)-amino or N-(pyridyl-C₁₋₃-alkyl)-amino group wherein in each case a hydrogen atom of the abovementioned amino groups may be substituted by a C₁₋₃-alkylsulphonyl, phenyl-C₁₋₃-alkylsulphonyl or phenylsulphonyl group or by a C₁₋₇-alkyl group which may be replaced in the 2 to 5 position by a C₁₋₃-alkoxy, cyano, amino, C₁₋₃-alkylamino, di-(C₁₋₃-alkyl)-amino or tetrazolyl group,

by an aminocarbonyl or C₁₋₃-alkylaminocarbonyl group which may in each case be substituted at the amino-nitrogen atom

- 10 by a C₁₋₄-alkyl group which may be substituted by a vinyl, ethynyl, phenyl, pyridyl, imidazolyl, carboxy or trifluoromethyl group or, with the exception of the 2 position relative to the aminocarbonyl nitrogen atom, by a hydroxy, C₁₋₃-alkoxy, C₁₋₃-alkylthio, amino, C₁₋₃-alkylamino, di-(C₁₋₃-alkyl)-amino, C₁₋₄-alkanoylamino or C₁₋₅-alkoxycarbonylamino group,
- 15 by a C₃₋₇-cycloalkyl, C₅₋₉-azabicycloalkyl, phenyl, pyridyl, C₁₋₃-alkoxy or di-(C₁₋₃-alkyl)-amino group,
- 20 by a C₁₋₃-alkyl group which is substituted by a piperidin-3-yl or piperidin-4-yl group optionally substituted in the 1 position by a C₁₋₃-alkyl or C₁₋₅-alkoxycarbonyl group, or
- 25 by an amino, C₁₋₃-alkylamino or phenyl-C₁₋₃-alkylamino group optionally substituted at the amino-nitrogen atom by a C₁₋₄-alkanoyl, C₁₋₅-alkoxycarbonyl, benzoyl, pyrrolidino, piperidino, morpholino or N-(C₁₋₃-alkyl)-piperazino group,
- 30 by a carbonyl group substituted by a pyrrolidino, pyrrolino, piperidino, morpholino or N-(C₁₋₃-alkyl)-piperazino group,

by a sulphonyl group substituted by an amino, C₁₋₃-alkylamino, di-(C₁₋₃-alkyl)-amino, pyrrolidino, piperidino, morpholino or N-(C₁₋₃-alkyl)-piperazino group,

5 by an amino or N-(C₁₋₃-alkyl)-amino group which may in each case be substituted at the amino-nitrogen atom by an aminocarbonyl, C₁₋₃-alkylaminocarbonyl, phenyl-C₁₋₃-alkylaminocarbonyl, phenylaminocarbonyl, phenoxyphenylaminocarbonyl, pyridylaminocarbonyl, pyrrolidinocarbonyl, piperidinocarbonyl, morpholinocarbonyl or N-(C₁₋₃-alkyl)-piperazinocarbonyl group, wherein additionally any hydrogen atom of one of the abovementioned aminocarbonyl groups present may be substituted by a 10 C₁₋₃-alkyl group,

by a 5- or 6-membered heteroaryl group,

15 by a dihydro-oxazolyl, dihydro-imidazolyl, 2-oxo-pyrrolidino, 2-oxo-piperidino or 2-oxo-hexamethyleneimino group to which a phenyl ring may be fused via two adjacent carbon atoms,

20 by an ethynyl group substituted by a phenyl, hydroxymethyl or dimethylamino group, whilst

25 additionally the abovementioned mono- or disubstituted phenyl groups may be substituted by another fluorine, chlorine or bromine atom or by one or two other C₁₋₃-alkyl or C₁₋₃-alkoxy groups and two C₁₋₃-alkoxy groups in the o position may be replaced by a methylenedioxy group,

and the abovementioned 6-membered heteroaryl groups contain one, two or three nitrogen atoms and the abovementioned 5-membered heteroaryl groups contain an imino group optionally substituted by a C₁₋₃-alkyl group, an oxygen or sulphur atom or an imino group optionally substituted by a C₁₋₃-alkyl group substituted and an oxygen or sulphur atom or 30 one or two nitrogen atoms and additionally a phenyl ring may be fused to the abovementioned monocyclic heteroaryl groups via two adjacent carbon atoms, this phenyl

10032555-010202

ring optionally being substituted in the carbon skeleton by a fluorine, chlorine or bromine atom or by a C₁₋₃-alkyl or C₁₋₃-alkoxy group, whilst the abovementioned 5-membered monocyclic heteroaryl groups in the carbon skeleton may additionally be substituted by a C₁₋₄-alkyl, trifluoromethyl, phenyl or furanyl group and by another C₁₋₃-alkyl group,

5

and the amino and imino groups mentioned in the definition of the abovementioned groups may additionally be substituted by a group which may be cleaved *in vivo*,

or a physiologically acceptable salt thereof.

10

4. A compound of the formula I, according to claim 3, wherein:

B and R₂ to R₅ are defined as in claim 3,

15

R₁ denotes a hydrogen atom or a C₁₋₃-alkyl group and

A denotes a phenyl, naphthyl or tetrahydronaphthyl group substituted by a fluorine, chlorine, bromine or iodine atom or by a C₁₋₆-alkyl, C₃₋₇-cycloalkyl, phenyl, C₁₋₃-alkoxy, trifluoromethyl or nitro group, whilst the abovementioned monosubstituted phenyl and naphthyl groups may additionally be substituted by a fluorine, chlorine or bromine atom or by a C₁₋₃-alkyl or C₁₋₃-alkoxy group, with the proviso that

20 A does not denote a phenyl group which may be mono- or disubstituted by halogen atoms, C₁₋₄-alkyl or C₁₋₃-alkoxy groups, wherein the substituents may be identical or different, and does not represent a 4-biphenyl or pentylphenyl group if

25 R₁ and R₂ each denote a hydrogen atom or a C₁₋₄-alkyl group,

R₃ denotes a hydrogen atom,

30 R₄ and R₅ each denote a hydrogen atom or

2020 RELEASE UNDER E.O. 14176

R₄ and R₅ together denote another carbon-carbon bond and
B denotes a carboxyphenyl or methoxycarbonylphenyl group,

a naphthyl group,

5

a chromane or chromene group wherein a methylene group may be replaced by a carbonyl group,

10 a 5- or 6-membered heteroaryl group optionally substituted in the carbon skeleton by a fluorine, chlorine or bromine atom or by a C₁₋₃-alkyl or C₁₋₃-alkoxy group, whilst the 6-membered heteroaryl groups contain one, two or three nitrogen atoms and the 5-membered heteroaryl groups contain an imino group optionally substituted by a C₁₋₃-alkyl group, an oxygen or sulphur atom or an imino group optionally substituted by a C₁₋₃-alkyl group and an oxygen or sulphur atom or one or two nitrogen atoms and additionally a phenyl ring
15 15 may be fused to the abovementioned monocyclic heteroaryl groups via two adjacent carbon atoms, whilst said phenyl ring may also be substituted in the carbon skeleton by a fluorine, chlorine or bromine atom or by a C₁₋₃-alkyl or C₁₋₃-alkoxy group,

the isomers thereof and the salts thereof.

20

5. A compound of the formula I according to claim 3, wherein:

R₁ denotes a hydrogen atom or a C₁₋₃-alkyl group,

25 25 R₂ denotes a hydrogen atom or a methyl group or, if R₄ and R₅ each denote a hydrogen atom, R₁ and R₂ together denote a methylene bridge,

R₃ denotes a hydrogen atom or a C₁₋₅-alkyl group,

30 30 R₄ and R₅ together denote another carbon-carbon bond,

A denotes a phenyl group substituted by a fluorine, chlorine, bromine or iodine atom or by a C₁₋₅-alkyl, cyclohexyl, phenyl, methoxy, cyano or trifluoromethyl group,

a phenyl group substituted by fluorine, chlorine or bromine atoms, by methyl or methoxy

5 groups, whilst the substituents may be identical or different, or

a C₁₋₃-alkylphenyl group, which is disubstituted by fluorine, chlorine or bromine atoms, whilst the substituents may be identical or different, with the proviso that

10 A does not denote a phenyl group which is substituted by a halogen atom, by a methyl, pentyl, C₁₋₃-alkoxy or phenyl group or by two C₁₋₃-alkoxy groups, if

R₃ denotes a hydrogen atom,

R₄ and R₅ each denote a hydrogen atom or

15 R₄ and R₅ together denote another carbon-carbon bond and
B denotes a carboxyphenyl or methoxycarbonylphenyl group,

and A does not denote a phenyl group which is substituted by a methyl or phenyl group if

20

R₁ and R₂ each denote a hydrogen atom,

R₃ denotes a hydrogen atom,

R₄ and R₅ together denote another carbon-carbon bond and
B denotes a carboxyphenyl or methoxycarbonylphenyl group,

25

a naphthyl group optionally substituted by a fluorine, chlorine or bromine atom or by a methyl or methoxy group,

a tetrahydronaphthyl group,

30

a chromene group wherein a methylene group is replaced by a carbonyl group,

40037555-0102

a pyridyl, benzofuryl, benzothienyl, quinolyl or isoquinolyl group optionally substituted by a methyl group and

5 B denotes a cyclohexyl, trimethoxyphenyl, methylenedioxyphenyl, naphthyl, pyridyl, thienyl, pyrazolyl, quinolyl or isoquinolyl group substituted by a carboxy group,

10 a phenyl group substituted by a carboxy, methoxycarbonyl, ethoxycarbonyl, hydroxymethyl, sulpho, tetrazolyl, methylsulphonylaminocarbonyl or phenylsulphonylaminocarbonyl group, which may additionally be substituted

by a fluorine, chlorine, bromine or iodine atom,

15 by a methyl, trifluoromethyl, phenyl, hydroxymethyl, hydroxy, methoxy, methylsulphonyloxy, 2-dimethylamino-ethoxy, carboxy, nitro, methylsulphonylamino, phenylsulphonylamino, aminosulphonyl, pyrrolidino, piperidino or morpholino group,

20 by a methyl group which is substituted by an amino, C₁₋₃-alkylamino, cyclopentylamino, pyrrolidino or piperidino group,

by an amino, N-methyl-amino or N-(2-methoxy-ethyl)-amino group which may in each case be substituted at the amino-nitrogen atom

25 by a C₁₋₇-alkyl or phenyl group,

by an ethyl group which is substituted in the 1 or 2 position by a phenyl or pyridyl group,

30 by a C₂₋₄-alkyl group which is terminally substituted by a methoxy, cyano, dimethylamino or tetrazolyl group,

- by an acetyl, benzoyl, C₁₋₅-alkoxycarbonyl, aminocarbonyl or methylaminocarbonyl group, whilst the aminocarbonyl moiety of the abovementioned groups may in each case additionally be substituted by an optionally phenyl-substituted C₁₋₃-alkyl group, by a phenyl, phenoxyphenyl or pyridyl group,
- 5
- by a methylsulphonyl, phenylsulphonyl or benzylsulphonyl group,
- 10
- by an aminocarbonyl or methylaminocarbonyl group which may in each case be substituted at the amino-nitrogen atom
- 15
- by a C₁₋₄-alkyl, C₃₋₆-cycloalkyl, phenyl, benzyl, pyridyl, pyridylmethyl or methoxy group,
- 20
- by a methyl group which is substituted by a vinyl, ethynyl, trifluoromethyl, C₇₋₉-azabicycloalkyl, carboxy or imidazolyl group or by a piperidin-4-yl group optionally substituted in the 1 position by a methyl or C₁₋₅-alkoxycarbonyl group,
- 25
- by a straight-chain or branched C₂₋₃-alkyl group substituted in the 2 or 3 position by a hydroxy, methoxy, methylthio, amino, acetylamino, C₁₋₅-alkoxycarbonylamino, carboxy-, C₁₋₅-alkoxycarbonyl or dimethylamino group,
- by a pyrrolidino, piperidino, morpholino, 4-methyl-piperazino, amino or methylamino group, whilst the abovementioned amino and methylamino groups may each additionally be substituted at the amino-nitrogen atom by a methyl, acetyl, benzoyl or C₁₋₅-alkoxycarbonyl group,

PROTECTED BY
COPYRIGHT

by a dihydro-oxazolyl, dihydro-imidazolyl, 2-oxo-pyrrolidino, 2-oxo-piperidino or 2-oxo-hexamethyleneimino group to which a phenyl ring may be fused via two adjacent carbon atoms,

5 by an imidazolyl or 4-methyl-imidazolyl group optionally substituted by a methyl, ethyl or phenyl group, to which a phenyl ring may additionally be fused via two adjacent carbon atoms,

10 a pyrazolyl group optionally substituted by a C₁₋₄-alkyl or furanyl group, which may additionally be substituted by a methyl or trifluoromethyl group,

15 by an ethynyl group substituted by a phenyl, hydroxymethyl or dimethylamino group, whilst

20 additionally the abovementioned mono- or disubstituted phenyl groups may be substituted by another fluorine, chlorine or bromine atom or by one or two other methyl or methoxy groups,

or a physiologically acceptable salt thereof.

6. A compound of the formula I according to claim 3, wherein:

R₁ denotes a hydrogen atom or a C₁₋₃-alkyl group,

25 R₂ denotes a hydrogen atom or R₁ and R₂ together denote a methylene group, if R₄ and R₅ each simultaneously denote a hydrogen atom,

R₃ denotes a hydrogen atom,

30 R₄ and R₅ together denote another carbon-carbon bond,

EPO/EPO-REGISTRE/EGPC/EGPC

A denotes a phenyl or naphthyl group mono- or disubstituted by a fluorine, chlorine, bromine or iodine atom or by a C₁₋₆-alkyl, C₃₋₇-cycloalkyl or trifluoromethyl group, whilst the substituents may be identical or different, with the proviso that

5

A does not denote a phenyl group which may be mono- or di-substituted by halogen atoms or C₁₋₄-alkyl groups, wherein the substituents may be identical or different, and does not denote a 4-biphenyl or pentylphenyl group if

10

R₁ denotes a hydrogen atom or a C₁₋₃-alkyl group,

R₂ denotes a hydrogen atom,

R₃ denotes a hydrogen atom,

R₄ and R₅ each denote a hydrogen atom or

R₄ and R₅ together denote another carbon-carbon bond and

15

B denotes a carboxyphenyl or methoxycarbonylphenyl group,

a naphthyl group,

a chromene group wherein a methylene group is replaced by a carbonyl group,

20

a benzothienyl group and

B denotes a phenyl, naphthyl, thienyl or pyridinyl group, each of which is substituted by a carboxy group, whilst the abovementioned phenyl groups may additionally be substituted

25

by a fluorine, chlorine or bromine atom,

by a C₁₋₃-alkyl, hydroxy, C₁₋₃-alkoxy, C₁₋₃-alkylsulphonyloxy, pyrrolidino, piperidino, morpholino or N-(C₁₋₃-alkyl)-piperazino group,

30

by an n-C₂₋₃-alkoxy, C₂₋₃-alkenyl or C₂₋₃-alkynyl group substituted in the 2 or 3 position by a di-(C₁₋₃-alkyl)-amino group,

5 by an N-methyl-N-(n-C₂₋₃-alkyl)-amino group substituted in the 2 or 3 position by a di-(C₁₋₃-alkyl)-amino group,

by a di-(C₁₋₃-alkyl)-amino group,

10 by an imidazolyl or pyrazolyl group optionally substituted by a C₁₋₄-alkyl group,

15 by a C₁₋₄-alkylaminocarbonyl, N-(pyridinylmethyl)-aminocarbonyl, pyrrolidinoaminocarbonyl or piperidinoaminocarbonyl group and

may additionally be substituted by another fluorine atom, by another C₁₋₃-alkyl or
15 C₁₋₃-alkoxy group,

or a physiologically acceptable salt thereof.

20 7. A compound of the formula I according to claim 3, wherein:

R₁ denotes a methyl group,

R₂ denotes a hydrogen atom,

25

R₃ denotes a hydrogen atom,

R₄ and R₅ together denote another carbon-carbon bond,

A denotes a phenyl group substituted by two chlorine or bromine atoms or by a chlorine atom and a bromine atom, a naphthyl, 2-oxo-chromene or benzothienyl group, with the proviso that

- 5 A does not denote a phenyl group disubstituted by halogen atoms if

R₁ denotes a methyl group,

R₂ denotes a hydrogen atom,

R₃ denotes a hydrogen atom,

- 10 R₄ and R₅ each denote a hydrogen atom or

R₄ and R₅ together denote another carbon-carbon bond and

B denotes a carboxyphenyl or methoxycarbonylphenyl group,

- 15 and B denotes a 2-carboxy-phenyl, 2-carboxy-thienyl or 2-carboxy-pyridinyl group, whilst
the abovementioned 2-carboxy-phenyl group may additionally be substituted in the phenyl
nucleus

by a fluorine, chlorine or bromine atom,

- 20 by a C₁₋₃-alkyl, hydroxy, C₁₋₃-alkoxy, C₁₋₃-alkylsulphonyloxy or morpholino group,

by an n-C₂₋₃-alkoxy group substituted in the 2 or 3 position by a di-(C₁₋₃-alkyl)-
amino group,

- 25 by an N-methyl-N-(n-C₂₋₃-alkyl)-amino group substituted in the 2 or 3 position by a
di-(C₁₋₃-alkyl)-amino group,

by an imidazolyl or pyrazolyl group optionally substituted by a C₁₋₄-alkyl group,

- 30 by a C₁₋₄-alkylaminocarbonyl, N-(pyridinylmethyl)-aminocarbonyl,
pyrrolidinoaminocarbonyl or piperidinoaminocarbonyl group and

may additionally be substituted by another fluorine atom or by another methoxy group,

5 or a physiologically acceptable salt thereof.

8. A compound selected from the group consisting of:

10 (1) trans-3-(naphth-2-yl)-but-2-enoic acid-N-(2-carboxy-phenyl)-amide,

(2) trans-3-(naphth-2-yl)-but-2-enoic acid-N-(2-carboxy-4,5-dimethoxy-phenyl)-amide,

(3) trans-3-(naphth-2-yl)-but-2-enoic acid-N-(2-carboxy-4-fluoro-phenyl)-amide,

15 (4) trans-3-(naphth-2-yl)-but-2-enoic acid-N-(2-carboxy-4,5-difluoro-phenyl)-amide,

(5) trans-3-(naphth-2-yl)-but-2-enoic acid-N-(2-carboxy-5-fluoro-phenyl)-amide,

20 (6) trans-3-(naphth-2-yl)-but-2-enoic acid-N-(2-carboxy-4-methoxy-5-methyl-phenyl)-amide,

(7) trans-3-(naphth-2-yl)-but-2-enoic acid-N-[2-carboxy-4-(morpholin-4-yl)-phenyl]-amide,

25 (8) trans-3-(naphth-2-yl)-but-2-enoic acid-N-(2-carboxy-4-dimethylamino-phenyl)-amide,

(9) trans-3-(naphth-2-yl)-but-2-enoic acid-N-(2-carboxy-4-hydroxy-phenyl)-amide,

30 (10) trans-3-(naphth-2-yl)-but-2-enoic acid-N-(3-carboxy-thiophen-4-yl)-amide,

DO NOT INDEX

(11) trans-3-(naphth-2-yl)-but-2-enoic acid-N-[2-carboxy-4-(imidazol-1-yl)-phenyl]-amide,

(12) trans-3-(2-oxo-2H-chromen-3-yl)-but-2-enoic acid-N-(2-carboxy-phenyl)-amide,

5

(13) trans-3-(naphth-2-yl)-but-2-enoic acid-N-[2-carboxy-4-(imidazol-1-yl)-5-fluoro-phenyl]-amide,

(14) trans-3-(benzothiophen-2-yl)-but-2-enoic acid-N-(2-carboxy-phenyl)-amide,

10

(15) trans-3-(naphth-2-yl)-but-2-enoic acid-N-(2-carboxy-4-methanesulphonyloxy-phenyl)-amide,

15

(16) trans-3-(naphth-2-yl)-but-2-enoic acid-N-[2-carboxy-4-(2-N,N-dimethylamino-ethoxy)-phenyl]-amide,

20

(17) trans-3-(naphth-2-yl)-but-2-enoic acid-N-(4-carboxy-pyridin-3-yl)-amide,

(18) trans-3-(3,4-dichlorophenyl)-but-2-enoic acid-N-(2-carboxy-4,5-dimethoxy-phenyl)-amide,

25

(19) trans-3-(3-chloro-4-bromophenyl)-but-2-enoic acid-N-(2-carboxy-phenyl)-amide,

(20) trans-3-(naphth-2-yl)-but-2-enoic acid-N-(2-carboxy-6-methyl-phenyl)-amide,

25

(21) trans-3-(naphth-2-yl)-but-2-enoic acid-N-(2-carboxy-6-fluoro-phenyl)-amide,

(22) trans-3-(naphth-2-yl)-but-2-enoic acid-N-[2-carboxy-5-(propylaminocarbonyl)-phenyl]-amide,

30

- (23) trans-3-(naphth-2-yl)-but-2-enoic acid-N-[2-carboxy-5-(pyrrolidin-1-yl-aminocarbonyl)-phenyl]-amide,
- (24) trans-3-(naphth-2-yl)-but-2-enoic acid-N-[2-carboxy-5-(N-(pyridin-3-yl-methyl)-aminocarbonyl)-phenyl]-amide,
5
- (25) trans-3-(naphth-2-yl)-but-2-enoic acid-N-(2-carboxy-6-chloro-phenyl)-amide
- or a physiologically acceptable salt thereof.

10

9. A pharmaceutical composition containing a compound according to
claim 3 together with one or more inert carriers and/or diluents.

15

DO NOT RESEND - DRAFT